

STANDARD OPERATING PROCEDURE FOR ASSESSMENT OF RISK ASSOCIATED WITH RESEARCH STUDIES SPONSORED BY NHS FIFE

SOP NUMBER:	Fife R&D SOP 07
AUTHOR:	Aileen Yell
ISSUE DATE:	18 Nov 2020
EFFECTIVE DATE:	18 Nov 2020
REVIEW DATE:	18 Nov 2022

1. PURPOSE

This document describes the process to be followed by the NHS Fife Research & Development (R&D) Department for performing a Sponsor Risk Assessment and corresponding Mitigation Plan, where required, as part of the Sponsorship Review process.

It is the responsibility of all staff using this SOP to ensure they are using the latest version. The latest version is available via the Research & Development (R&D) pages on StaffLink and on the NHS Fife website (www.nhsfife.org/research). For guidance, contact the R&D Department via fife.randd@nhs.scot.

2. APPLICABILITY

This SOP applies to all staff involved in submitting and reviewing applications for proposed research Sponsorship by NHS Fife.

3. POLICY

- 3.1 The Risk Assessment process for research studies applying for Sponsorship by NHS Fife ensures that the R&D Department has completed a comprehensive review of the research application and has identified appropriate actions to mitigate any identified risks, prior to providing an "in principle" decision to Sponsor the Study.
- 3.2 The Risk Assessment is dependent on the study team's level of experience and the capabilities of NHS Fife e.g. a high risk study by an experienced research team may be addressed by routine management processes, whereas a low risk study by an inexperienced research team may require additional management actions to mitigate potential risk.
- 3.3 The Risk Assessment is also dependent on the current circumstances in NHS Fife at that particular time, e.g. whether key resources or staff are available or unavailable when the study is expected to be delivered.

4. PROCEDURE

- 4.1 The R&D Research Coordinator must complete the Risk Assessment Decision Flow Chart (Doc Ref 07-01) to identify if a Risk Assessment is required as part of the Sponsor Review Process (See SOP06(Fife) - Sponsor Agreement for Research Projects Involving Humans, Their Tissue and/or Data), and document the decision.
- 4.2 In cases of research requiring a Risk Assessment, the process will be started by the R&D Research Coordinator who will liaise with the Chief Investigator (CI), research team members and key staff members for any relevant Support Departments to

Uncontrolled when printed.

Please visit <u>www.nhsfife.org/research</u> to guarantee adherence to the latest version of this SOP.

Effective Date: 18 Nov 2020



complete the Risk Assessment Form (Doc Ref 07-02) to assess the potential risks associated with the specific research application.

- 4.3 The Risk Assessment Form considers the following areas of risk for NHS Fife from the perspective of a research Sponsor:
 - Clinical Trial of Investigational Medicinal Product
 - Device study
 - Participants rights and safety
 - Facilities, Equipment and Resources
 - · Study Design and Reliability of Results
 - Documentation, Governance and Compliance

Each area has a set of specific questions. The answers will be subject to a likelihood (Low, Medium and High) score. Mitigation strategies should be documented to address all concerns identified.

- 4.4 A meeting between the R&D Research Coordinator, CI, members of the study team, and key staff members for any relevant Support Departments is a mandatory requirement. The purpose of this meeting is to discuss the Risk Assessment in detail, and to talk through any mitigation plans. This will be followed up by the R&D Research Coordinator by email, summarising the outcome of the meeting.
- 4.5 The Risk Assessment Form will be updated as risk mitigation is completed. The Risk Assessment Form will be revisited during the life cycle of the study if any material changes are made to the study documentation, staffing or operational circumstances.
- 4.6 The completed Risk Assessment Form will be reviewed by the Assistant R&D Director and Medical Director to assess the mitigation decisions for any study that has high likelihood risk scores or any issues identified during the initial risk assessment. In some cases, the Assistant R&D Director and Medical Director may decide that the risk to NHS Fife as Sponsor is too high and in such cases, Sponsorship will be declined.
- 4.7 The Risk Assessment process will be used to inform the Monitoring Plan (See Fife R&D SOP 30 Monitoring Research).

5. ASSOCIATED DOCUMENTS

Doc Ref 07-01 - Risk Assessment Decision Flow Chart

Doc Ref 07-02 - Risk Assessment Form

SOP06 - Sponsor Agreement for Research Projects Involving Humans, Their Tissue and/or Data.

SOP 30 - Monitoring Research

6. ABBREVIATIONS

CI Chief Investigator R&D Research and Development

7. REFERENCES

UK Policy Framework for Health and Social Care Research

Uncontrolled when printed.

Please visit <u>www.nhsfife.org/research</u> to guarantee adherence to the latest version of this SOP.

Effective Date: 18 Nov 2020



 $\underline{\text{https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/}.$

8. DOCUMENT HISTORY

Version Number:	Edited by (job title):	Effective Date:	Details of Revisions Made:
1	Julie Aitken R&D Trials Facilitator	13/12/2017	N/A – new SOP
2	Aileen Yell R&D Research Coordinator	18 Nov 2020	Minor amendments to text only.

9. APPROVAL

APPROVED BY	Date
Prof Alex Baldacchino, Research, Development & Innovation Director, NHS Fife	17 Nov 2020
Signature: A Dalo	

Effective Date: 18 Nov 2020